{"id":"gm102-expansion","_chembl":null,"_dailymed":null,"_scrapedAt":"2026-03-28T02:39:05.442Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123875,"model":"claude-sonnet-4-5-20250929"},"description":"GM102 is an investigational therapeutic agent being developed by GamaMabs Pharma currently in Phase 2 clinical trials. The drug represents an expansion of the GM102 program, though specific molecular targets and therapeutic applications have not been publicly disclosed by the company.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT03799731","phase":"PHASE2","title":"Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers","status":"COMPLETED","sponsor":"GamaMabs Pharma","startDate":"2018-07-11","conditions":"Colorectal Cancer","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GM102 expansion","genericName":"GM102 expansion","companyName":"GamaMabs Pharma","companyId":"gamamabs-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}